...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of cellular physiology. >Zinc transporter LIV1: A promising cell surface target for triple negative breast cancer
【24h】

Zinc transporter LIV1: A promising cell surface target for triple negative breast cancer

机译：锌转运蛋白LIV1：三阴性乳腺癌的有前途的细胞表面靶点

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Breast cancer is one of the leading causes contributing to the global cancer burden. The triple negative breast cancer (TNBC) molecular subtype accounts for the most aggressive type. Despite progression in therapeutic options and prognosis in breast cancer treatment options, there remains a high rate of distant relapse. With advancements in understanding the role of zinc and zinc carriers in the prognosis and treatment of the disease, the scope of precision treatment/targeted therapy has been expanded. Zinc levels and zinc transporters play a vital role in maintaining cellular homeostasis, tumor surveillance, apoptosis, and immune function. This review focuses on the zinc transporter, LIV1, as an essential target for breast cancer prognosis and emerging treatment options. Previous studies give an insight into the role of LIV1 in fulfilling the most important hallmarks of cancer such as apoptosis, metastasis, invasion, and evading the immune system. Normal tissue expression of LIV1 is limited. Higher expression of LIV1 has been linked to Epithelial‐Mesenchymal Transition, histological grade of cancer, and early node metastasis. LIV1 was found to be one of the attractive targets in the therapeutic hunt for TNBCs. TNBCs are an immunogenic breast cancer subtype. As zinc transporters are known to serve as the metabolic gatekeepers of immune cells, this review bridges tumor infiltrating lymphocytes, TNBC and LIV1. In addition, the suitability of LIV1 as an antibody‐drug conjugate (Seattle genetics [SGN]‐LIV1A) target in TNBC, represents a promising strategy for patients. Early clinical trial results reveal that this novel agent reduces tumor burden by inducing mitotic arrest, immunomodulation, and immunogenic cell death, warranting further investigation of SGN‐LIV1A in combination with immuno‐oncology agents. Priming the patient's immune response in combination with SGN‐LIV1A could eventually change the landscape for the TNBC patient population.
机译：抽象的乳腺癌是一个领先的原因导致全球癌症负担。三阴乳腺癌(TNBC)分子亚型占最多积极的类型。在乳腺癌治疗的选择及预后癌症治疗方法,仍然是一个高遥远的复发。了解锌和锌运营商的角色在疾病的预后和治疗,精密治疗和靶向治疗的范围一直在扩大。转运蛋白在维护发挥至关重要的作用肿瘤细胞内稳态,监视,细胞凋亡和免疫功能。关注的是锌转运体、LIV1,作为一个乳腺癌预后的关键目标新兴的治疗方案。一个洞察LIV1完成的角色最重要的标志癌症等细胞凋亡、转移、入侵和逃避免疫系统。是有限的。地理与上皮间充质转变,组织学分级的癌症,早期的节点转移。在治疗寻找有吸引力的目标TNBCs。亚型。免疫细胞的代谢守门,本文桥梁肿瘤浸润淋巴细胞,TNBC LIV1。适用性LIV1作为抗体药物共轭(西雅图遗传学(胡志明市)必经LIV1A) TNBC的目标,代表了一种有前途的战略。早期临床试验结果显示,这个小说剂诱导减少肿瘤负荷有丝分裂逮捕、免疫调节和免疫原性细胞死亡,需要进一步的调查胡志明市LIV1A结合免疫检测肿瘤代理。结合胡志明市LIV1A最终可能改变TNBC患者的景观人口。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号